# Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer

> **NCT00003232** · PHASE3 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 227 (actual)

## Conditions studied

- Pain
- Prostate Cancer
- Quality of Life

## Interventions

- **DRUG:** clodronate disodium
- **DRUG:** mitoxantrone hydrochloride
- **DRUG:** prednisone
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT00003232
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-11-24
- **Primary completion:** 2002-05-01
- **Final completion:** 2009-02-10
- **Target enrollment:** 227 (ACTUAL)
- **Last updated:** 2020-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003232, "Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00003232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*